Description
Carfilzomib Brand names available in India?
Carfilzomib is the generic name of the medication and is its international nonproprietary name. Carfilzomib is marketed under the brand name Kyprolis among others.
Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth.
Kyprolis® was approved by the U.S. Food and Drug Administration in July 2015, in combination with lenalidomide and dexamethasone, for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis® is also indicated under FDA accelerated approval as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an
immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, tissue found inside most bones where normal blood cells are produced.
Will this product be accessible across all regions of India?
The product – Kyprolis (Carfilzomib) Injection will be available across India on request. Carfilzomib is available in all the major cities in India – Delhi, Chandigarh, Jodhpur, Patna, Kolkata, Lucknow, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune. To get or place an order from Aark Pharmaceuticals, a pharma distributor in India, please call us at+91 9999156233, You can also make an inquiry by emailing us at sales@aarkpharma.co.in, sales@aarkpharma.com, WhatsApp: +91 9999156233.
References
- Dr Reddy’s to market three Amgen drugs in India.
- Amgen gets cosier with Dr. Reddy’s, adding three marketed drugs to Indian partnership.
- Dr. Reddy’s to Market and Distribute Amgen’s RepathaTM (evolocumab), Kyprolis® (carfilzomib) and BLINCYTO® (blinatumomab) in India upon Approval
